This survey report explores what biopharma executives have to say about current and future plans to integrate AI into commercial processes. AI adoption is proceeding much more slowly in pharmaceutical commercialization than it has in drug discovery. While AI promises to transform commercial decision-making into a much more data-driven, proactive discipline, adoption and maturity vary widely across organizations and even individual business units. Pharmaceutical leaders are on the threshold of reimagining commercialization for the AI era. This survey report explores what 150 biopharma executives across the U.S., Canada, and the U.K. had to say about their companies’ current and future plans to integrate AI into commercial processes. If harnessed effectively and built on the right data foundation, AI has big potential in commercialization. Highlights include: Seven key findings on how biopharmaceutical leaders think about AI transformation. How AI is being tested for many commercialization use cases, and why ROI is uneven. General-purpose vs. purpose-built pharma-specific tools, and how they are being used.
